Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients

Singh, Avinash Kumar; Hussain, Salman; Ahmed, Rayaz; Agrawal, Narendra; Klugar, Miloslav; Sharma, Manju

doi:10.1111/nep.14014

Cited by 8 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the authors reported an increased rate of CTR-CVTs in the imatinib cohort when compared to patients treated with 2G-TKIs [119]. A recent meta-analysis confirmed these data, reporting a significantly higher risk of renal impairment (CKD or AKI) in patients treated with imatinib than other TKIs (RR 2.7 IC 95% 1.49-4.91) [64].…”

Section: Renal Function Impairmentmentioning

confidence: 84%

“…Renal dysfunction associated with TKIs, especially imatinib and bosutinib [64,65], can further increase cardiovascular risk [66]. Pieces of evidence in the literature have reported this association and several hypotheses have been advanced.…”

Section: Renal Impairmentmentioning

confidence: 99%

“…Recommendations: Based on the aforementioned evidence, TKIs have been shown to be safe when administered at standard doses in patients with modest levels of renal dysfunction. Imatinib and, to a lesser extent, bosutinib, have been associated with renal dysfunction in long-term management [64,65]. According to expert opinions, patients can be treated with the most suitable TKI and subjected to careful monitoring of their kidney function, with dose optimization if necessary.…”

Section: Renal Function Impairmentmentioning

confidence: 99%

See 2 more Smart Citations

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia

Costa

Pittorru

Caocci

et al. 2023

Hemato

View full text Add to dashboard Cite

Since their introduction, tyrosine kinase inhibitors (TKIs) have radically changed the treatment paradigm of Chronic Myeloid Leukemia (CML), leading to deep and lasting molecular responses and profoundly influencing survival. However, cancer-therapy-related Cardiovascular Toxicities (CTR-CVTs) associated with BCR::ABL1 TKIs are one of the main sources of concern: hypertension, arterial occlusive events, arrhythmias, dysmetabolic alteration, and glomerular filtration impairment are frequently reported in clinical trials and real-life experiences. Therefore, a close interaction between hematologists and cardiologists becomes crucial to implementing prevention protocols based on a comprehensive assessment of baseline cardiovascular risk, the management of any detectable and modifiable risk factors, and the elaboration of a monitoring plan for CTR-CVTs during treatment. Here, we provide the most comprehensive and recent evidence in the literature on the pathophysiological patterns underlying CTR-CVTs, providing useful evidence-based guidance on the prevention and management of CVD risk factors at baseline and during treatment with BCR::ABL1 TKIs.

show abstract

Section: Renal Function Impairmentmentioning

confidence: 84%

Section: Renal Impairmentmentioning

confidence: 99%

Section: Renal Function Impairmentmentioning

confidence: 99%

See 1 more Smart Citation

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia

Costa

Pittorru

Caocci

et al. 2023

Hemato

View full text Add to dashboard Cite

show abstract

“…The goal of diagnosis and management of AKI during cancer therapy should be to mitigate the sequelae of these events on optimal cancer treatment. [137,138] Ribociclib [138,139] 12-60% 20-59% 44-61% ATN, AIN [134], Hypokalemia (21%), Hyponatremia (12%) Hypokalemia (13%), Hyponatremia (9%), Hypercalcemia (7%) Hypokalemia (15%), hypocalcemia (14%), Hyponatremia (15%) PARP INH [140] Olaparib Niraparib Rucaparib 20-30% 20-30% 11-30% [141] HTN (19%) [142] BCR-ABL INH Imatinib [143][144][145] Dasatinib [146][147][148] 6-13%…”

Section: Discussionmentioning

confidence: 99%

Cancer drugs and acute kidney injury: new therapies and new challenges

Gork,

Xiong,

Kitchlu

2024

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of review Cancer therapies continue to evolve at a rapid pace and although novel treatments, including immunotherapies and targeted therapies have allowed for substantial improvements in cancer survival, they carry associated risks of acute kidney injury (AKI). We aim to summarize the existing literature on AKI associated with the spectrum of systemic cancer treatments, including conventional chemotherapies, newer immunotherapies, and the growing number of targeted cancer therapies, which may be associated with both AKI and ‘pseudo-AKI’. Recent findings Conventional cytotoxic chemotherapies (e.g. cisplatin and other platinum-based agents, methotrexate, pemetrexed, ifosfamide, etc.) with well recognized nephrotoxicities (predominantly tubulointerstitial injury) remain in widespread use. Immunotherapies (e.g., immune checkpoint inhibitors and CAR-T therapies) may be associated with kidney immune-related adverse events, most often acute interstitial nephritis, and rarely, glomerular disease. Recently, multiple targeted cancer therapies have been associated with reduced renal tubular secretion of creatinine, causing elevations in serum creatinine and apparent ‘pseudo-AKI’. To complicate matters further, these agents have had biopsy-proven, ‘true’ kidney injury attributed to them in numerous case reports. Summary Clinicians in nephrology and oncology must be aware of the various potential kidney risks with these agents and recognize those with clinically meaningful impact on both cancer and kidney outcomes.

show abstract

“…13 There is a dearth of evidence concerning the effect of imatinib on renal impairment and the incidence of anaemia in patients with CML. 14,15 A few studies have reported imatinib-related renal dysfunction and haematological toxicity. 16 Measuring creatinine concentration is not a reliable test for renal function; glomerulus filtration rate (GFR) estimation is a reliable or more validated assessment tool.…”

Section: Introductionmentioning

confidence: 99%

Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients

Singh

Vidyadhari

Bhurani

et al. 2023

J Oncol Pharm Pract

Self Cite

View full text Add to dashboard Cite

Purpose In this study, we investigate renal function and anaemia during imatinib treatment in patients with chronic myeloid leukaemia. Methods The patients with chronic myeloid leukaemia with chronic phase who had been treated with only imatinib for 12 months at Rajiv Gandhi Cancer Institute and Research Centre (New Delhi, India) were enrolled and prospectively analysed. The chronic renal impairment parameters, including estimated glomerular filtration rate and haemoglobin levels for anaemia from June 2020 to June 2022, were monitored in newly diagnosed in patients with chronic myeloid leukaemia-chronic phase. The data were analysed by SPSS software version 22. Results In total 55 patients with chronic myeloid leukaemia chronic phase who had been on imatinib for 12 months were monitored. The mean estimated glomerular filtration rate was significantly decreased (74 ± 14 to 59 ± 12 mL/min/1.73m2, p < 0.001) with a decrease in mean haemoglobin levels after 12 months (10.9 ± 2.01 to 9.0 ± 1.02, p < 0.004). The decreased estimated glomerular filtration rate was negatively correlated with haemoglobin levels after 1 year of imatinib administration (correlation coefficient = 0.892, R2 = 0.7976, p < 0.05). Conclusion We recommended close monitoring of renal function and haemoglobin levels in patients with chronic myeloid leukaemia patients.

show abstract

Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients

Cited by 8 publications

References 33 publications

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia

Cancer drugs and acute kidney injury: new therapies and new challenges

Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients

Contact Info

Product

Resources

About